Welcome to our dedicated page for Mainz Biomed NV SEC filings (Ticker: MYNZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating the real story inside a pre-revenue biotech’s filings can feel overwhelming. Mainz Biomed’s disclosures mix complex PCR science, clinical trial data, and fast-moving capital raises—details investors can’t ignore. If you’ve ever asked, “Where do I find the Mainz Biomed quarterly earnings report 10-Q filing?” or struggled to decode a Form 4 before the market opens, this page is built for you.
Stock Titan’s platform turns that complexity into clarity. Our AI instantly delivers Mainz Biomed SEC filings explained simply, highlighting how R&D spending supports ColoAlert’s commercialization, when pipeline milestones trigger expenses, and which risks appear in each Mainz Biomed annual report 10-K simplified. Need to monitor management moves? Receive Mainz Biomed Form 4 insider transactions real-time alerts and dive deeper into Mainz Biomed insider trading Form 4 transactions alongside concise context—no manual page flipping required.
Every filing type is here, refreshed the moment EDGAR releases it. Compare quarter-over-quarter trends with Mainz Biomed earnings report filing analysis, scan Mainz Biomed 8-K material events explained for trial updates, or review the Mainz Biomed proxy statement executive compensation section to see how equity grants align with clinical goals. Whether you’re understanding Mainz Biomed SEC documents with AI for the first time or tracking Mainz Biomed executive stock transactions Form 4 ahead of pivotal readouts, our summaries, real-time feeds, and expert commentary surface what matters so you can focus on decisions, not document mining.
Mainz Biomed (MYNZ) entered an Equity Distribution Agreement with Maxim Group, permitting at-the-market sales of ordinary shares up to $10,000,000. The company disclosed that up to $2,300,000 of these shares may be sold under its effective Form F-3 shelf and a prospectus supplement dated October 3, 2025.
Sales, if any, may occur on Nasdaq or other U.S. markets, via methods permitted by law, including block trades. Mainz Biomed will pay a 3.0% sales commission to the agent. The company is not obligated to sell, and the agreement ends upon selling all offered shares or termination by either party.
Mainz Biomed N.V. filed a 424B5 prospectus supplement describing an at-the-market offering and summarizing key risks and capitalization. The company states it is an early-revenue stage business that has incurred operating losses since inception and may not reach profitability. Its commercial product ColoAlert is licensed and sold in Europe, while PancAlert remains an early-stage research candidate. The prospectus discloses potential dilution from outstanding instruments including up to 14,054,763 ordinary shares underlying warrants, 461,836 options, and 25,000 shares from convertible notes. It reports recent issuances of 1,321,000 ordinary shares since July 1, 2025 and net proceeds of approximately $2.6 million from sale of 2,222,222 pre-funded units, and contemplates sale of approximately $2.3 million of ordinary shares in this offering on a pro forma, as-adjusted basis. The filing lists numerous standard securities, regulatory, operational and market risks, and notes prior reverse-split activity to meet Nasdaq minimum bid-price requirements.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 723,092 ordinary shares of Mainz Biomed N.V., representing 9.99% of the class. The filing states Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and that Armistice exercises shared voting and dispositive power over 723,092 shares while neither Armistice nor Mr. Boyd claim sole voting or dispositive power. The Master Fund is identified as the party with the right to receive dividends or sale proceeds. The filing clarifies these holdings are reported to be held in the ordinary course of business and not for the purpose of changing control.
Transaction summary: On August 4, 2025, Mainz Biomed N.V. entered into a Securities Purchase Agreement to sell 2,222,222 pre-funded units, closing on August 5, 2025, for expected gross proceeds of approximately $3,000,000 before fees and expenses.
Each pre-funded unit consists of one pre-funded warrant (exercisable immediately at a remaining exercise price of $0.001) and one-and-one-half ordinary warrants (exercisable immediately at $1.35 per share, expiring five years from issuance). Ordinary warrants include anti-dilution protections for dividends, splits and similar transactions. Mainz paid the placement agent a fee equal to 7% of gross proceeds plus $85,000 in fixed fees. The SPA and related warrant forms were filed as exhibits to the Form F-1 and information is incorporated into the Form F-3 registration statement.
FAQ
What is the current stock price of Mainz Biomed NV (MYNZ)?
What is the market cap of Mainz Biomed NV (MYNZ)?
